07:00 , Jun 27, 2016 |  BC Week In Review  |  Company News

Cipher, Edesa Biotech deal

Cipher granted Edesa rights to ASF-1096 to treat anorectal disorders. Cipher retains rights to dermatological indications. ASF-1096, a 0.5% cream formulation of the R-enantiomer of salbutamol (albuterol), has completed Phase II testing to treat discoid...
07:00 , Mar 9, 2015 |  BC Week In Review  |  Company News

Astion, Cipher deal

Astion granted Cipher exclusive, worldwide rights to develop and commercialize Dermadexin , Pruridexin and ASF-1096 . Dermadexin and Pruridexin are topical barrier-repair creams containing Astion’s pyridine-3-carboxamide glyceryl monocaprylate (P3CGM). Dermadexin is approved for seborrheic dermatitis...
07:00 , Jun 19, 2008 |  BC Innovations  |  Cover Story

Moving Velcade into Lupus

Memory B cells and short- and long-lived plasma cells secrete autoantibodies that are thought to be at the root of lupus. 1,2 Short-lived plasma cells can be targeted indirectly by blocking B cell activation, but...
07:00 , May 15, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Fatty acid amide hydrolase (FAAH); monoacylglycerol lipase (MAGL) A study in mice suggests that inhibiting FAAH and MAGL could help...
08:00 , Feb 28, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain; inflammation; sleep disorders Fatty acid amide hydrolase (FAAH) An SAR study identified a-ketooxazole analogs as FAAH inhibitors that could be...
08:00 , Jan 7, 2008 |  BC Week In Review  |  Clinical News

ASF-1096 regulatory update

EMEA's Committee for Orphan Medical Products (COMP) granted Orphan Drug designation for Astion's ASF-1096 to treat cutaneous lupus erythematosus. The 0.5% cream formulation of the R-enantiomer of salbutamol (albuterol) is in Phase IIb testing for...
08:00 , Dec 17, 2007 |  BC Week In Review  |  Clinical News

ASF-1057: Phase III started

Astion began an international Phase III trial in 500 patients with moderate to severe facial seborrheic dermatitis to compare ASF-1057 vs. neutral moisturizing cream or placebo. Astion Pharma A/S , Copenhagen, Denmark   Product: ASF-1057...
08:00 , Dec 17, 2007 |  BC Week In Review  |  Clinical News

ASF-1057: Phase III started

Astion began an international Phase III trial in 700 patients with moderate to severe facial seborrheic dermatitis to compare topical ASF-1057 vs. 2% ketoconazole cream or placebo. Astion Pharma A/S , Copenhagen, Denmark   Product:...
07:00 , Aug 6, 2007 |  BC Week In Review  |  Clinical News

ASF-1096 regulatory update

EMEA's Committee for Orphan Medicinal Products (COMP) issued a positive opinion to grant Orphan Drug designation for Astion's ASF-1096 to treat cutaneous forms of lupus erythematosus. The 0.5% R-salbutamol cream is in Phase IIb testing...
07:00 , Apr 23, 2007 |  BC Week In Review  |  Company News

Astion board of directors update

Astion Pharma A/S , Copenhagen, Denmark   Business: Inflammation, Dermatology   Appointed: Flemming Ornskov, president and CEO of LifeCycle Pharma A/S , as chairman; and Flemming Pedersen, president and CEO of NeuroSearch A/S  ...